RANDOM-EFFECTS META-ANALYSIS OF PHASE I DOSE-FINDING STUDIES USING STOCHASTIC PROCESS PRIORS

• 成果类型: Article
• 署名作者: Ursino, Moreno; Roever, Christian; Zohar, Sarah; Friede, Tim
• 署名单位: Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; University of Gottingen; UNIVERSITY GOTTINGEN HOSPITAL
• 刊物名称: ANNALS OF APPLIED STATISTICS
• ISSN/ISSBN: 1932-6157
• DOI: 10.1214/20-AOAS1390
• 发表日期: 2021
• 页码: 174-193
• 关键词: factor receptor inhibitor; days on/7 days; clinical-trials; raf kinase; combination therapy; irinotecan cpt-11; japanese patients; sorafenib; s-1; pharmacokinetics

摘要

Phase I dose-finding studies aim at identifying the maximum tolerated dose (MTD). Often, several dose-finding studies are conducted with some variation in the administration mode or dose panel. For instance, sorafenib (BAY 43-900) was used as monotherapy in 36 phase I trials, according to a recent clinicaltrials.gov search. Since the toxicity may not be directly related to the specific indication, synthesizing the information from several studies might be worthwhile. However, this is rarely done in practice and only a fixed-effect meta-analysis framework was proposed to date. We developed a Bayesian random-effects meta-analysis methodology to pool several phase I trials and suggest the MTD. A curve free hierarchical model on the logistic scale with random effects, accounting for between-trial heterogeneity, is used to model the probability of toxicity across the investigated doses. An Ornstein-Uhlenbeck Gaussian process is adopted for the random effects structure. Prior distributions for the curve-free model are based on a latent Gamma process. An extensive simulation study showed good performance of the proposed method also under model deviations. Sharing information between phase I studies can improve the precision of MTD selection, at least when the number of trials is reasonably large.